Gallium Ga-68 Gozetotide is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68. It was first introduced by Univ California Los Angeles in its drug Gallium Ga 68 Gozetotide on Dec 1, 2020. Other drugs containing Gallium Ga-68 Gozetotide are Locametz, Illuccix. 4 different companies have introduced drugs containing Gallium Ga-68 Gozetotide.

Gallium Ga-68 Gozetotide Patents

Given below is the list of patents protecting Gallium Ga-68 Gozetotide, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Locametz	US12109277		Mar 09, 2036	Novartis
Illuccix	US11027031	Kit for radiolabelling	Jul 28, 2035	Telix
Locametz	US11369590	PSMA binding ligand-linker conjugates and methods for using	Aug 15, 2028	Novartis

Add above patents to watchlist

Gallium Ga-68 Gozetotide's Family Patents

Full family tree